Masato Komuro

Pharmacist at National Center for Global Health and Medicine, Tokyo. JSPHCS-certified Oncology Pharmacist #Hematology #Myeloma #AYA #Oncofertility #JOP #PEP

[Masato Komuro @KomuroMasato]

My impression is that the infectious risk driven by CD19 targeting cannot be overlooked. When we translate this into daily clinical practice, robust outpatient management—such as rigorous prophylaxis and monitoring—will be the key to success.

[Graham Collins @graham74GC]

FrontMIND data interesting (Lenz et al)
• tafa-len-RCHOP v RCHOP IPI3-5 LBCL
• 3y PFS ⬆️ 6-7%
• higher in centrally r/v DLBCL
• no signif OS
• more tox: haem & GI
• no COO difference
• tafa weekly for all 6 cycles
Does benefit overcome tox & logistic impact.
#EHA2026

[Masato Komuro @KomuroMasato]

@DrJFriedberg @chadinabhan @JCO_ASCO An excellent insight. This latest data is indeed the final piece of the puzzle. It’s a wonderful breakthrough that definitively resolves a major clinical dilemma, ultimately leading to better, more compassionate patient outcomes. Time to change the practice.

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm #IMWG26

Nice figure @myelomaMD on how to improve KM curve. Focus on improving outcomes for high risk disease

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm #IMWG26

A glimpse on the future centred about cure in myeloma with limited duration therapy

[Open Medicine @OpenMedicineHQ]

Newly Diagnosed Myeloma from @VincentRK: https://t.co/3GnbnIe4P1

[LARVOL @Larvol]

Here's our list of the Top 30 Oncology Conferences worldwide to help keep track of the major meetings shaping cancer research and clinical practice in 2026.

From global congresses to disease-specific meetings, these conferences are where many of the most important trial readouts and discussions happen.

Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI26 #GU26 #ASCO26 #EHA26 #AACR26 #ESMO26 #SITC26 #ASH26 #SABCS26 #2026Events #MedicalConferences

The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO | @sitcancer | @IASLC | @SocietyofHemOnc | @AACR

[Masato Komuro @KomuroMasato]

Double awards today! 🏆
1."Idea Award" at a workflow contest. Didn't win the top prize, but glad my casual idea made the finals!
2."Encouragement Award" for my paper. A huge team effort, so I'm genuinely happy we gained this prestige.
https://t.co/ICQwDLtBct

[Eddie Cliff @Eddie_Cliff]

#ASH23 Late Breaking Abstract 1

PERSEUS
Newly-Diagnosed Myeloma
RCT 709 patients
Dara-VRd vs VRd

- 48-month PFS rates 84.3% vs 67.7%, HR 0.42, p<0.001
- OS: D-VRd 34 deaths [9.6%]; VRd, 44 deaths [12.4%] (immature)

https://t.co/lLudIrZTP0 #mmsm

[Mindset Machine  @mindsetmachine]

8 Japanese Techniques to Overcome Laziness

| Thread

[Vincent Rajkumar @VincentRK]

How I treat acute light chain cast nephropathy in myeloma. #MedTwitter @MayoMyeloma @BloodCancerJnl #OpenAccess https://t.co/ovnVlNfCHb

[Binod Dhakal @bhemato]

KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple My... https://t.co/OhzSMoCJXp

[Graham Collins @graham74GC]

A sobering slide.

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Oral ixazomib, lenalidomide, and dexamethasone [IRd] for newly diagnosed transplant-ineligible multiple myeloma [TI NDMM] patients [Mar 24, 2021] Facon et al. @VincentRK @BloodJournal https://t.co/bN6Y2LLYPY #mmsm

[Masato Komuro @KomuroMasato]

The paper has been published.
I'm very happy!!
I would like to thank everyone involved.

https://t.co/pxNDIkSKOx

[Masato Komuro @KomuroMasato]

ERd is recommended for RRMM after daratumumab VTD therapy, but can it be expected to be effective in treatment...

[Felipe Peña-Muñoz @HematoRules]

2021 multiple myeloma @myESMO guideline. Excellent work

[Blood Advances @BloodAdvances]

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia https://t.co/urDMWasJST

[Masato Komuro @KomuroMasato]

In Japan, the rejection of vaccines is very strong.

Fear of adverse reactions. Politicians should be the first to administer them.

A long time ago, they were begging for a vaccine to be developed...

I think Japanese people really have low medical literacy.

[Marcos de Lima @DrMarcosdelima]

A picture is worth a 1000 words.

[Muzaffar Qazilbash @Transplant_Doc]

VRD +/- elotuzumab in untreated, high-risk multiple myeloma (SWOG-1211): a randomised, phase 2 trial. N=100. Median PFS 31.4 and 33.6 month, with or without elo (HR: 0.968, p=0.45) https://t.co/nuW3xDSACs @szusmani @Myeloma_Doc @VincentRK #mmsm #MYELOMA

[Masato Komuro @KomuroMasato]

It shows the overwhelming management power of Taiwan.
Is it because the government agencies that manage it are so great, or is it because the health literacy of the people is so high?

[Eric Topol @EricTopol]

One per thousand Americans have now died from covid-19.
How does that compare with 12 other select countries with >20 million population?